Albany Molecular Research
|21 Corporate Circle,
PO Box 15098,
United States of America
Albany Molecular Research is a chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. We conduct R&D; projects and collaborate with many leading pharmaceutical, biotechnology and genomics companies, and develop new chemistry technology for potential prescription drug applications.
Further Information: http://www.albmolecular.com
Novel Lewis Acid Catalyzed (E)/(Z)-Arylidene Thiohydantoin Formation
The novel Lewis acid catalyzed condensation of aldehydes with 3-alkyl-1-methyl-thioxo-imidazolidin-4-ones (thiohydantoins) to generate the corresponding (E)/(Z) 5-arylidene-3-alkyl-1-methyl-2-thioxo-imidazolidin-4-ones (arylidene thiohydantoins) is presented. A survey of various catalysts was conducted (either indium(III) triflate, aluminum trichloride, or boron trifluoride diethyl etherate) and compared with the uncatalyzed reactions.
Related news from our archive
AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division
Dr. Guaciaro has assumed leadership responsibility for Company's Hungarian facilities, and is relocating to Budapest.
AMRI Completes Strategic European Acquisition
The completed acquisition provides Albany Molecular Research with an immediate presence in Europe.
Albany Molecular Research, Inc. Opens New Facilities in Singapore and India
Albany opens its first laboratory in India and its Singapore subsidiary moves into permanent laboratory facilities.